Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
123.85
-0.08 (-0.06%)
At close: Aug 28, 2026, 4:00 PM EDT
123.41
-0.44 (-0.36%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Inhibrx Biosciences Revenue
In the year 2025, Inhibrx Biosciences had annual revenue of $1.30M with 550.00% growth.
Revenue (ttm)
$1.30M
Revenue Growth
+550.00%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
110
Market Cap
1.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.30M | 1.10M | 550.00% |
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
| Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
| Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
| Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
| Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
| Dec 31, 2018 | 8.60M | 204.00K | 2.43% |
| Dec 31, 2017 | 8.39M | 1.72M | 25.86% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.68B |
| Lakefront Biotherapeutics NV | 1.13B |
| Immunocore Holdings | 430.78M |
| Vir Biotechnology | 303.23M |
| Syndax Pharmaceuticals | 252.25M |
| Septerna | 98.88M |
| Intellia Therapeutics | 59.51M |
| Recursion Pharmaceuticals | 54.86M |
INBX News
- 4 days ago - Inhibrx initiated with a Buy at H.C. Wainwright - TheFly
- 15 days ago - Inhibrx Reports Second Quarter 2026 Financial Results - PRNewsWire
- 15 days ago - Inhibrx Biosciences Quarterly report: Q2 2026 - Filings
- 15 days ago - Inhibrx Biosciences Earnings release: Q2 2026 - Filings
- 6 weeks ago - Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million - PRNewsWire
- 2 months ago - Inhibrx announces FDA acceptance of BLA for ozekibart - TheFly
- 2 months ago - Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma - PRNewsWire
- 3 months ago - Inhibrx price target raised to $325 from $300 at Stifel - TheFly